Alirocumab cuts nonfatal outcomes among statin-treated ACS survivors: ODYSSEY OUTCOMES

  • Szarek M & al.
  • J Am Coll Cardiol
  • 5 Feb 2019

  • curated by Jenny Blair, MD
  • Clinical Essentials
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.


  • For patients taking high-intensity statins after acute coronary syndrome (ACS), alirocumab (Praluent, Sanofi US and Regeneron Pharmaceuticals, Inc.) prevents approximately twice as many nonfatal events as first nonfatal events. 
  • Study furnishes additional evidence of benefit of alirocumab.
  • Editorial : “to analyze recurrent events in a clinical trial is atypical but, in the present case, very informative….[the study] provides a very encouraging signal.”

Why this matters

  • ODYSSEY OUTCOMES previously demonstrated lower first incidence of major cardiovascular (CV) events.
  • By accounting for death censoring otherwise potentially preventable recurrent nonfatal outcomes, this study aims to derive more accurate HRs.  

Key results

  • At 4 years, alirocumab vs placebo:
    • Number of total nonfatal CV events: 0.301 vs 0.357. 
    • Number of first nonfatal CV events: 0.160 vs 0.183.
  • Alirocumab vs placebo:
    • Total nonfatal cardiovascular events: HR, 0.87 (95% CI, 0.82-0.93).
    • Death: HR, 0.83 (95% CI, 0.71-0.97). 

Study design

  • Planned secondary analysis of ODYSSEY OUTCOMES, which compared alirocumab vs placebo added to maximal statin treatment after ACS (n=18,924). 
  • This study assessed alirocumab’s effect on total (first and subsequent) nonfatal CV events, all-cause deaths. 
  • Funding: Sanofi, Regeneron Pharmaceuticals, Inc., Fondation Assistance Publique—Hôpitaux de Paris.


  • Apparent links between nonfatal events and death might trace to residual confounding.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.